INTRODUCTION {#sec1-1}
============

Periodontitis, a local chronic inflammation in the supporting tissues of the teeth leading to progressive loss of the periodontal ligament and bone, is believed to result from disruption of the homeostatic balance between periodontopathic bacteria and the host response to these microorganisms.\[[@ref1]\]

The critical objectives of periodontal therapy include stopping the disease progression and resolving the inflammation.\[[@ref2]\] Mechanical debridement has been the most widely used approach, but many studies have shown that mechanical debridement alone cannot effectively eliminate most of the causative bacteria and it is usually associated with high recurrence rate.\[[@ref3][@ref4]\]

Several systemic antibiotics have been used for periodontal treatment to suppress or eliminate residual periodontal pathogens and thus serve as an adjunct to the conventional mechanical therapy.\[[@ref5]\] Unwanted side effects such as resistance, toxicity, sensitivity, growth of opportunistic infection and interaction with other medications are often encountered.\[[@ref3]\] Therefore, the local administration of antimicrobials can provide a useful solution to those complications.\[[@ref6]\]

Local drug delivery results in a high concentration of the administrated drug in the pocket, which can penetrate into the periodontal tissues as well. This dual effect on pocket microflora as well as on pathogens invading the tissue can result in enhanced clinical results without any systemic side effects and bacterial resistance. In addition, it provides 100-fold higher therapeutic doses of the agent in subgingival areas than systemic therapy.\[[@ref7][@ref8]\]

Natural products have served as a major source of drugs for centuries and about half of pharmaceuticals in use today are derived from natural products.\[[@ref9]\] Oriental medicines have been evaluated for their effects on periodontal disease, regarding the antibacterial and anti-inflammatory effects as well as the periodontal tissue regeneration.\[[@ref10]\] Among these materials, tea tree oil (TTO) is derived from the paper bark tea tree.\[[@ref11]\] TTO has a broad-spectrum antimicrobial, antifungal, antiviral, antioxidant and anti-inflammatory effect.\[[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]\] A few studies have shown the useful effect of the local application of TTO on periodontal diseases.\[[@ref11]\]

Pentraxin-3 (PXT3) is an inflammatory molecule that belongs to the same family of C-reactive protein (CRP), which is indeed a short PTX.\[[@ref18][@ref19]\] While CRP is produced in the liver mainly in response to interleukin-6 (IL-6), PTX3 is produced by the widely distributed innate immune cells including neutrophils, fibroblasts, dendritic cells, epithelial cells, macrophages and vascular endothelial cells in response to inflammatory mediators, such as IL-1, tumors necrosis factor-α (TNF-α) and bacterial products.\[[@ref20]\] Human PTX3 plasma levels increase in several pathological conditions including sepsis, acute myocardial infarction and small-vessel vasculitis.\[[@ref19][@ref21]\]

Gingival crevicular fluid (GCF) contains a variety of microbial and host products, including neutrophils, antibodies, complement proteins and cytokines.\[[@ref22]\] Recent studies by Pradeep *et al*.,\[[@ref23]\] and Fujita *et al*.,\[[@ref24]\] found increased concentration of PTX3 in GCF and they used it as a diagnostic marker for periodontal disease in patients with chronic periodontitis.

The current study was conducted to evaluate the effect of local application of TTO gel as an adjunctive treatment of moderate to severe chronic periodontitis regarding the clinical parameters and the level of long PXT3 in GCF.

MATERIALS AND METHODS {#sec1-2}
=====================

After approval of the Research Ethical Committee of Tanta University Egypt, we recruited 40 adult patients with chronic periodontitis (21 males and 19 females). The cases were selected from the outpatient Department of Oral Medicine, Faculty of Dentistry, 6^th^ October University and Tanta University from February 2011 to January 2012.

Inclusion criteria {#sec2-1}
------------------

Male and female subjects between the ages of 30 and 60 years were included in this study if they had:

Untreated moderate to severe chronic or recurrent periodontitis without periodontal surgery at least for the last 24 monthsSingle rooted teeth with probing pocket depth (PPD) of 5-8 mm, without any recession, that bled on probing at the initial visit.

Exclusion criteria {#sec2-2}
------------------

Subjects were excluded if they:

Had any systemic disease that affects the periodontiumWere pregnant or postmenopausal womenHad received any anti-inflammatory drugs, antibiotics or vitamins within the previous 3 monthsWere heavy smokers (\>10 cigarettes/day)History of alcohol abuseHad previous participation in other clinical trialsHad received scaling and root planing (SRP) subgingival instrumentation less than 2 months prior to the baseline examinationHad any teeth with a periodontal pocket extending to the apex because of possible endodontic/periodontal complications.

Materials {#sec2-3}
---------

Gel formulation was prepared from TTO (Melaleuca alternifolia) to be used as a locally delivered sustained release subgingival gel was prepared as follows:

To make the methyl cellulose gel, 7 g of methyl cellulose powder was dissolved in 100 ml boiled water. To make the TTO gel 5%, 5 ml of TTO (Sigma^®^ Steinheim, Germany) was then mixed into the methyl cellulose gel. The gel was sterilized in the autoclave at 110°C for 20 min.\[[@ref25]\]

Patient groups {#sec2-4}
--------------

Patients were divided randomly by random number table drawn up by a professor of statistics into two equal groups.

### Group I (control group) {#sec3-1}

Twenty patients were received oral hygiene instructions and full mouth SRP with hand instruments.

### Group II (test group) {#sec3-2}

Twenty patients were received oral hygiene instructions and full mouth SRP with hand instruments. After drying the area, the deepest selected periodontal pocket was filled with 5% TTO gel (immediately after completion of SRP) until the gel could be observed at the gingival margin. The gel applied sites were covered with periodontal pack (Coe-Pack). The patients were asked to return for replacement of the periodontal dressings if the dressing were dislodged before 7 days. No antibiotics, antiplaque or anti-inflammatory agents were prescribed after treatment. The patients were instructed to refrain from chewing hard or sticky foods, brushing near the TTO or using inter-dental aids and eating crusty foods for 1 week.

The dressing was removed after 7 days and the operation site was washed with sterile saline. Adverse effects were noted at recall visits (7 days, 1, 3, 6 months) and any supragingival deposits were removed.

Collection of GCF {#sec2-5}
-----------------

GCF samples were collected using paper strips from the deepest diseased site (pocket ≥5 mm). After isolation with cotton rolls to prevent contamination with saliva, supragingival plaque was removed with cotton pellets and the tooth was air-dried. The paper strips were carefully inserted into the crevice until mild resistance was felt and were left in place for 30 s. Samples visibly contaminated with blood were discarded. Three GCF samples from the same site were pooled. Paper strips with absorbed GCF were placed in microcentrifuge tubes containing 500 μl of phosphate-buffered saline. Tubes were vortexed for 45 min and centrifuged at 8000 rpm for 5 min. The supernatants were transferred into new microcentrifuge tubes and stored at −80°C until analysis.

PTX3 immunoassay {#sec2-6}
----------------

The PTX3 level in 20 μl of the GCF sample was determined using a commercial solid-phase sandwich enzyme-linked immunosorbent assay (Quantikine^®^ DPT × 30; R and D Systems Inc., Minneapolis, MN, USA) according to the manufacturer\'s protocol. It detects up to 0.65 ng/ml PTX3; with intra-assay and inter-assay CVs range from 3.8% to 4.4% and 4.1% to 6.1%, respectively. GCF was obtained from each site at baseline, 1, 3 and 6 months after treatment.

Clinical measurement {#sec2-7}
--------------------

The measurements described below were obtained only from the diseased site, at baseline, 1, 3 and 6 months after treatment:

Plaque index (PI)\[[@ref26]\]Gingival index (GI)\[[@ref27]\]PPD\[[@ref28]\]Clinical attachment level (CAL).\[[@ref28]\]

Statistical analysis {#sec2-8}
--------------------

All the results were tabulated and statistically analyzed using Statistical Package for Social Science (SPSS version 12). The difference between groups was statistically analyzed using independent sample *t*-test and intra-group analysis using paired *t*-test.

RESULTS {#sec1-3}
=======

All the patients completed the study without any complications. The patient in Group II complained of intensive and unpleasant taste of the TTO gel. At baseline, there was no significant difference in clinical parameters between the groups (*P* \> 0.01).

PI and GI {#sec2-9}
---------

The mean changes overtime in PI and GI are given in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} respectively.

###### 

Mean values of PI, GI and PPD among the study groups at base line, 1, 3 and 6 months after treatment

![](JISP-17-444-g001)

###### 

Mean values of CAL and PTX3 level among the study groups at base line, 1, 3 and 6 months after treatment

![](JISP-17-444-g002)

All subjects showed a statistically very highly clinical significant improvement in both gingival and plaque indices at follow-up visits when compared with the baseline levels. The mean reduction in PI score from baseline to 1, 3 and 6 months was (1.86 ± 0.52, 0.48 ± 0.22, 0.53 ± 0.23 and 0.50 ± 0.21 respectively) in Group I while in Group II was (1.67 ± 0.51, 0.46 ± 0.23, 0.48 ± 0.18 and 0.43 ± 0.15 respectively) (*P* \< 0.001).

Along with the evaluation periods, *t*-test showed a statistically very highly significant reduction of GI scores of Group I at 1, 3 and 6 months (0.55 ± 0.19, 0.65 ± 0.17 and 0.66 ± 0.26 respectively) and as compared with baseline values (2.17 ± 0.40). In addition, results of Group II revealed a statistically very highly significant reduction of GI scores, which reduced from (2.02 ± 0.40) at baseline to (0.33 ± 0.20, 0.37 ± 0.20 and 0.35 ± 0.17) at 1, 3 and 6 months respectively (*P* \< 0.001).

Intergroup comparison showed a statistically insignificant difference of the mean PI between the two treated groups at any evaluation periods when compared with each other (*P* \> 0.05). Comparing Group I and Group II at 1 and 3 months evaluation periods, results showed that the mean GI reduction was statistically highly significant (*P* \< 0.01) while at 6 months, the mean GI reduction was statistically very highly significant comparing the two tested groups (*P* \< 0.001) \[[Table 1](#T1){ref-type="table"}\].

PPD and CAL {#sec2-10}
-----------

Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} show changes in PPD and CAL for each treatment group. At baseline, there was no statistically significant difference in PDD or CAL of the treated sites.

All sites showed very highly significant changes in PDD and CAL from baseline to 1, 3 and 6 months. Mean reduction of PDD from baseline to 1, 3 and 6 months was (5.30 ± 0.47, 3.70 ± 0.47, 3.80 ± 0.41, 3.90 ± 0.44 respectively) in Group I and (5.25 ± 0.44, 3.35 ± 0.48, 3.30 ± 0.47 and 3.40 ± 0.50 respectively) in Group II. Also, the improvement in CAL in Group I was highly significant changed from (4.90 ± 0.78) at baseline to (3.50 ± 0.51, 3.60 ± 0.59, 3.70 ± 0.57) at 1, 3 and 6 months respectively while in Group II changed from (5.00 ± 0.79) at baseline to (3.12 ± 0.13, 3.20 ± 0.52, 3.25 ± 0.41) at 1, 3 and 6 months respectively (*P* \< 0.001).

Comparing Group I and Group II at 1, 3 and 6 months evaluation periods, *t*-test showed that the mean PPD reduction was statistically significant (*P* \< 0.05, *P* \< 0.01). Regarding CAL, when comparing Group I and Group II results showed a statistically significant improvement at 1, 3 and 6 months evaluation periods (*P* \< 0.001, *P* \< 0.05).

PTX3 level {#sec2-11}
----------

Results of Group I revealed that there was a very highly statistically significant reduction of PTX3 level at 1, 3 and 6 months post treatment. Results of Group II, showed a remarkable statistically significant reduction in the PTX3 level, which continued up to 6 months as compared with the mean baseline value (0.81 ± 0.29) while the mean value at 1, 3 and 6 months were 0.10 ± 0.04, 0.11 ± 0.04 and 0.12 ± 0.03. Intergroup comparison showed that the mean of PTX3 level at baseline was statistically insignificant between all treated groups. *t*-test showed a statistically highly significant improvement at 1 month evaluation period (*P* \< 0.01) while the mean PTX3 level showed a very remarkable reduction at 3 and 6 months when comparing the two tested groups (*P* \< 0.001).

DISCUSSION {#sec1-4}
==========

In the present study, the local TTO gel was investigated as a delivery system for an active agent to treat cases of chronic periodontitis. A part from the bad taste of the TTO, the patients didn't show any complications throughout the study periods. The studied groups consisted of untreated moderate chronic periodontitis patients; therefore, all of received the standard Phase I periodontal therapy. The treated teeth were single rooted to provide the standardization of mechanical instrumentation. It has reported that the surface irregularities, developmental difference in root anatomy and difficulties in getting better clinical outcomes, especially for the closed surgical interventions.

In this study, we examined the effect of TTO gel, on the clinical parameters and PTX3 level in patients with moderate to severe chronic periodontitis.

However, our results showed that there was a statistically significant reduction in the mean PI scores during the study periods in both groups as compared with baseline values and there was no significant difference between the two groups during the study periods. The reduction in plaque scores could be due to the proper oral hygiene maintenance after SRP. This was in agreement with the clinical results reported by Arweiler *et al*.,\[[@ref29]\] who described the efficacy of a TTO used as a mouthwash on plaque formation. They found that the PI in the group treated by TTO mouth wash did not differ from placebo mouthwash on any day from the study periods. Also, our results were in agreement with the other clinical results reported by Soukoulis and Hirsch,\[[@ref11]\] who performed a double-blind, longitudinal study to evaluate the effect of TTO gel (2.5%) applied to toothbrush twice daily. They found that TTO did not reduce plaque scores.

It was apparent in the present study that Group II (SRP plus TTO gel) showed a statistically significant reduction in gingival inflammation, which was maintained until the end of the study period as compared with Group I (SRP only). This could be attributed to the anti-inflammatory and antibacterial effect of the TTO. The antimicrobial action of TTO results from its ability to disrupt the permeability barrier of microbial membrane structures.\[[@ref30]\] These results are consistent with the study by Soukoulis and Hirsch,\[[@ref11]\] that revealed when the TTO gel was used twice daily with a toothbrush as a dentifrice, a significant reduction of gingival inflammation and bleeding was reported with severe gingivitis. In addition, improvement in gingival inflammation due to the anti-inflammatory activity of TTO has been also reported in other studies.\[[@ref16][@ref31][@ref32]\] Furthermore TTO may mediate its anti-inflammatory functions through the production of superoxide by human monocytes.\[[@ref16]\] Clinical improvements, reduction in PPD and gain in CAL seen following extensive SRP (alone) in Group I, are apparently due to reduction of inflammation secondary to alteration in the subgingival bacteria.\[[@ref33]\] In addition to the elimination of the local etiologic factors, it has been proposed that a scaling procedure may also elicit a local and systemic host response that would aid in eliminating local infection and promote healing.\[[@ref34]\]

In the current project, there was a statistically significant reduction in PPD and CAL in Group II compared to Group I during all evaluation periods. Arweiler *et al*.,\[[@ref29]\] and Saxer *et al*.,\[[@ref35]\] found that TTO was effective in reducing the oral bacteria. Furthermore, the component of TTO is known to have lipophilic properties, which facilitate its diffusion through epithelium.\[[@ref36]\] If TTO was readily absorbed after topical application into the gingival tissues and succeeded to enter the connective tissues, it would be a unique, non-toxic agent that could be a useful addition to the current range of chemotherapeutic periodontal treatment option.\[[@ref11]\]

The results of PX3 revealed that there was a statistically significant reduction in PX3 level in Group II when compared with Group I at all post treatment evaluation periods. Since, PTX3 is produced in response to inflammatory mediators, such as IL-1, TNF and bacterial products,\[[@ref20]\] our results could be in agreement with that of Juergens *et al*., who showed a significant decrease in the production of different cytokines (TNF-α and IL-1 β) from lipopolysaccharides (LPS) stimulated monocytes after administration of Soledum^®^ (containing 1, 8-cineole).\[[@ref31]\] Similar effects *in vitro* were reported on monocytes by other component of TTO like terpinen-4-ol.\[[@ref16][@ref32]\] Also, the reduction of PXT3 level in TTO group may be attributed to the antimicrobial effect of TTO, that decrease production of bacterial products like LPS which are responsible for stimulation of PTX3 production by immune cells.\[[@ref35]\]

CONCLUSIONS {#sec1-5}
===========

The findings of the current study suggest that, local application of TTO gel may provide some beneficial therapeutic effects to augment the results of SRP. Also, it emphasizes the potential therapeutic value of TTO as an anti-inflammatory agent, which is able to reduce inflammation and promote healing of periodontal tissues. Moreover, it places a focus on the value of monitoring GCF levels of PTX3 as a marker of periodontal tissue healing following various periodontal therapeutic approaches.

RECOMMENDATIONS {#sec1-6}
===============

Further human research is warranted to investigate the value of local application of TTO to augment different treatment modalities for periodontitis.
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